Skip to main content
padlock icon - secure page this page is secure

Open Access A multicenter, prospective, noninterventional study in a Norwegian cohort of patients with moderate-to-severe allergic rhinitis treated with MP-AzeFlu

Download Article:
(HTML 55.9 kb)
(PDF 1,524.3 kb)

Allergic Rhinitis and its Impact on Asthma guidelines recently recommended a treatment strategy for allergic rhinitis (AR) based on disease control rather than symptom severity by using a visual analog scale (VAS) to categorize control.


To evaluate the effectiveness of MP-AzeFlu (Dymista®) by using this VAS in routine clinical practice in Norway. MP-AzeFlu comprises a novel formulation that contains azelastine hydrochloride, fluticasone propionate and excipients delivered in a single spray.


This multicenter, prospective, noninterventional study enrolled patients (n = 160) with moderate-to-severe AR and acute symptoms who were eligible to receive treatment with MP-AzeFlu according to its summary of product characteristics. Patients assessed symptom severity by using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) in the morning before MP-AzeFlu use on days 0, 1, 3, 7, and after ∼14 days. On day 3, the patients assessed their level of disease control as well controlled, partly controlled, or uncontrolled. The proportion of Norwegian patients who achieved defined VAS score cutoffs for “well-controlled” and “partly controlled” AR were also calculated.


MP-AzeFlu reduced the mean ± standard deviation VAS score from 68.1 ± 16.4 mm at baseline to 37.4 ± 25.9 mm on the last day, a reduction of 30.8 ± 27.2 mm. The results were consistent, irrespective of disease severity, phenotype (i.e., seasonal AR [SAR], perennial AR [PAR], SAR plus PAR, unknown) or age (i.e., 12‐17, 18‐65, and >65 years). Of the patients (with recorded data), 88.1% considered their symptoms to be partly or well controlled at day 3; and 19.5, 32.0, 50.0, and 61.0% of the patients achieved a ≤38 mm well-controlled VAS score cutoff on days 1, 3, 7, and the last day, respectively.


MP-AzeFlu provided rapid sustained symptom control in a routine clinical practice in Norway, which provided support for its effectiveness for the treatment of AR in real life.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: Azelastine; MP-AzeFlu; Norway; control; effectiveness; fluticasone propionate; perennial allergic rhinitis; real-life; seasonal allergic rhinitis; visual analog scale

Document Type: Research Article

Affiliations: 1: From the Department of Otorhinolaryngology, Division of Head, Neck and Reconstructive Surgery, Oslo University Hospital Rikshospitalet, Oslo, Norway 2: Bærum Øre Nese Halsklinikk, Bekkestua, Norway 3: Sørlandet Hospital, Department of Otolaryngology, Head and Neck Surgery, Kristiansand, Norway

Publication date: 01 October 2017

More about this publication?
  • Allergy and Rhinology will no longer be hosted on Ingenta Connect as of July 10, 2018. For all subscription orders where the customer's end-user address is in the USA, Canada, Central and South America including the Caribbean, please contact [email protected] For all subscription orders where the customer's end user address is in the UK, Europe, Middle East, Africa and Australasia, please contact [email protected]
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more